Piracetam Obolenskoe, 30 pcs., 800 mg, film-coated tablets
Piracetam activates associative processes in the central nervous system, improves mood, memory and mentality in sick and healthy people. Stimulates intellectual activity and integrative activity of the brain, facilitates learning processes, improves connections between the cerebral hemispheres and synaptic conduction in the cortex, increases mental performance, stabilizes and restores impaired brain functions (memory, consciousness, speech). Piracetam normalizes the ratio of ADP and ATP (inhibits nucleotide phosphatase and activates adenylate cyclase), increases the activity of phospholipase A, stimulates bioenergetic and plastic processes in nervous tissue, and accelerates the exchange of neurotransmitters.
Piracetam increases the resistance of brain tissue to toxic influences and hypoxia, enhances the synthesis of phospholipids and nuclear RNA, enhances glycolytic processes and glucose utilization in the brain. Piracetam blocks platelet aggregation, improves microcirculation, optimizes the ability of red blood cells to pass through microvessels and the conformational properties of the red blood cell membrane, and increases regional blood flow in ischemic areas of the brain. Piracetam increases beta and alpha activity on the EEG and decreases delta activity. Reduces vestibular nystagmus. During hypoxia, intoxication, trauma, electroconvulsive effects have a neuroprotective effect.
Due to its antihypoxic effect, piracetam is effective in the complex treatment of myocardial infarction. Piracetam does not have anxiolytic or sedative effects.
Piracetam is absorbed almost completely and quickly after oral administration. Bioavailability is 100%. When 2 g of the drug is taken orally, the maximum plasma concentration is 40–60 mcg/ml after 30 minutes. Piracetam does not bind to plasma proteins. After 2–8 hours, the maximum concentration in the cerebrospinal fluid is created. Piracetam penetrates into all tissues and organs, and penetrates the placental barrier. Almost not metabolized. Selectively accumulates in the cerebral cortex, mainly in the parietal, frontal and occipital lobes, basal ganglia and cerebellum. The half-life of piracetam from plasma is 4–5 hours; from the cerebrospinal fluid is 6–8 hours. More than 95% of the drug is excreted unchanged by the kidneys after 30 hours. In patients with renal failure, the half-life is prolonged.
Piracetam obolenskoe
Manufacturer: FP OBOLENSKOYE CJSC (Russia)
tab., cover coated, 400 mg: 10, 15, 20, 30, 40, 45, 50, 60, 70, 75, 80, 90, 100, 105, 120, 135, 140, 150, 160, 180, 200, 210, 240 , 270, 300 or 360. Reg. No.: P No. 001564/01
Clinical and pharmacological group:
Nootropic drug
Release form, composition and packaging
Film-coated tablets
yellow, round, biconvex, oblong in shape with rounded ends, with a notch; On a cross section, two layers are visible.
| 1 tab. | |
| piracetam | 400 mg |
Excipients:
polyethylene glycol 6000, croscarmellose sodium (primellose), magnesium stearate, colloidal silicon dioxide (aerosil), hydroxypropylcellulose, titanium dioxide, quinoline yellow.
10 pieces. — cellular contour packages (3) — cardboard packs. 10 pieces. — contour cell packaging (6) — cardboard packs. 10 pieces. — cellular contour packages (1) — cardboard packs. 10 pieces. — contour cell packaging (5) — cardboard packs. 10 pieces. — contour cell packaging (4) — cardboard packs. 10 pieces. — contour cell packaging (7) — cardboard packs. 10 pieces. — contour cell packaging (8) — cardboard packs. 10 pieces. — contour cell packaging (9) — cardboard packs. 10 pieces. — contour cell packaging (10) — cardboard packs. 10 pieces. — contour cell packaging (12) — cardboard packs. 15 pcs. — contour cell packaging (12) — cardboard packs. 15 pcs. — cellular contour packages (1) — cardboard packs. 15 pcs. — cellular contour packages (3) — cardboard packs. 15 pcs. — contour cell packaging (2) — cardboard packs. 15 pcs. — contour cell packaging (4) — cardboard packs. 15 pcs. — contour cell packaging (5) — cardboard packs. 15 pcs. — contour cell packaging (6) — cardboard packs. 15 pcs. — contour cell packaging (7) — cardboard packs. 15 pcs. — contour cell packaging (8) — cardboard packs. 15 pcs. — contour cell packaging (9) — cardboard packs. 15 pcs. — contour cell packaging (10) — cardboard packs. 20 pcs. — contour cell packaging (10) — cardboard packs. 20 pcs. — cellular contour packages (1) — cardboard packs. 20 pcs. — contour cell packaging (2) — cardboard packs. 20 pcs. — cellular contour packages (3) — cardboard packs. 20 pcs. — contour cell packaging (5) — cardboard packs. 20 pcs. — contour cell packaging (6) — cardboard packs. 20 pcs. — contour cell packaging (7) — cardboard packs. 20 pcs. — contour cell packaging (8) — cardboard packs. 20 pcs. — contour cell packaging (9) — cardboard packs. 20 pcs. — contour cell packaging (12) — cardboard packs. 30 pcs. — contour cell packaging (12) — cardboard packs. 30 pcs. — cellular contour packages (1) — cardboard packs. 30 pcs. — contour cell packaging (2) — cardboard packs. 30 pcs. — cellular contour packages (3) — cardboard packs. 30 pcs. — contour cell packaging (4) — cardboard packs. 30 pcs. — contour cell packaging (5) — cardboard packs. 30 pcs. — contour cell packaging (6) — cardboard packs. 30 pcs. — contour cell packaging (7) — cardboard packs. 30 pcs. — contour cell packaging (8) — cardboard packs. 30 pcs. — contour cell packaging (9) — cardboard packs. 30 pcs. — contour cell packaging (10) — cardboard packs.
Description of the active components of the drug "Piracetam"
pharmachologic effect
Nootropic drug. It has a positive effect on metabolic processes and blood circulation in the brain. Increases glucose utilization, improves metabolic processes, improves microcirculation in ischemic areas, inhibits aggregation of activated platelets. It has a protective effect against brain damage caused by hypoxia, intoxication, and electric shock. Improves integrative brain activity. Does not have a sedative or psychostimulating effect.
Indications
Memory impairment, dizziness, decreased concentration, emotional lability, dementia due to cerebrovascular accidents (ischemic stroke), brain injury, Alzheimer's disease, in old age; comatose states of vascular, traumatic or toxic origin; treatment of abstinence and psychoorganic syndrome in chronic alcoholism; learning disabilities in children not associated with inadequate training or characteristics of the family environment (as part of combination therapy); sickle cell anemia (as part of combination therapy).
Dosage regimen
Adults orally - 30-160 mg/kg/day in 2-4 doses. Duration of treatment is 6-8 weeks.
If necessary, apply intramuscularly or intravenously at an initial dose of 10 g/day. When administered intravenously to patients in severe condition, the daily dose can be 12 g. After clinical improvement, the dose is gradually reduced and switched to oral administration.
Children orally - 30-50 mg/kg/day in 2-3 doses. Treatment should be continued for at least 3 weeks.
Side effect
From the digestive system:
rarely - dyspeptic symptoms, abdominal pain.
From the side of the central nervous system:
rarely - nervousness, agitation, irritability, anxiety, sleep disorders, dizziness, headache, tremor, in some cases - weakness, drowsiness.
Other:
increased sexual activity.
Contraindications
Hemorrhagic stroke, severe renal failure (with CC<20 ml/min), hypersensitivity to piracetam.
Pregnancy and lactation
Adequate and strictly controlled studies of the safety of piracetam during pregnancy have not been conducted. Use is possible only in cases where the expected benefit to the mother outweighs the possible risk to the fetus.
Piracetam appears to pass into breast milk. If it is necessary to use it during lactation, the issue of stopping breastfeeding should be decided.
In experimental studies
In animals, no negative effects of piracetam on the fetus were detected.
Use for renal impairment
Contraindicated in severe renal failure (creatinine clearance <20 ml/min).
Use with caution in patients with renal failure. Continuous monitoring of renal function indicators is recommended.
special instructions
Use with caution in patients with severe hemostatic impairment, during major surgical operations and severe bleeding; with renal failure.
Continuous monitoring of renal function indicators is recommended.
If sleep disturbances occur, it is recommended to stop taking piracetam in the evening and add this dose to the daytime dose.
Drug interactions
A case of interaction of piracetam with simultaneous use with a thyroid extract containing triiodothyronine and tetraiodothyronine is described, when the patient experienced anxiety, irritability and sleep disorders.
When used simultaneously with thyroid hormones, the development of central effects is possible - tremor, anxiety, irritability, sleep disturbances, confusion.
With the simultaneous use of central nervous system stimulants, the psychostimulating effect may be enhanced.
When used simultaneously with antipsychotics, an increase in extrapyramidal disorders is observed.
Drug interactions
A case of interaction of piracetam with simultaneous use with a thyroid extract containing triiodothyronine and tetraiodothyronine is described, when the patient experienced anxiety, irritability and sleep disorders.
When used simultaneously with thyroid hormones, the development of central effects is possible - tremor, anxiety, irritability, sleep disturbances, confusion.
With the simultaneous use of central nervous system stimulants, the psychostimulating effect may be enhanced.
When used simultaneously with antipsychotics, an increase in extrapyramidal disorders is observed.
Piracetam Tablets, 30 pcs., 800 mg, for oral administration, film-coated
Pharmacological properties
Piracetam activates associative processes in the central nervous system, improves mood, memory and mentality in sick and healthy people.
Stimulates intellectual activity and integrative activity of the brain, facilitates learning processes, improves connections between the cerebral hemispheres and synaptic conduction in the cortex, increases mental performance, stabilizes and restores impaired brain functions (memory, consciousness, speech). Piracetam normalizes the ratio of ADP and ATP (inhibits nucleotide phosphatase and activates adenylate cyclase), increases the activity of phospholipase A, stimulates bioenergetic and plastic processes in nervous tissue, and accelerates the exchange of neurotransmitters. Piracetam increases the resistance of brain tissue to toxic influences and hypoxia, enhances the synthesis of phospholipids and nuclear RNA, enhances glycolytic processes and glucose utilization in the brain. Piracetam blocks platelet aggregation, improves microcirculation, optimizes the ability of red blood cells to pass through microvessels and the conformational properties of the red blood cell membrane, and increases regional blood flow in ischemic areas of the brain. Piracetam increases beta and alpha activity on the EEG and decreases delta activity. Reduces vestibular nystagmus. During hypoxia, intoxication, trauma, electroconvulsive effects have a neuroprotective effect.
Due to its antihypoxic effect, piracetam is effective in the complex treatment of myocardial infarction. Piracetam does not have anxiolytic or sedative effects.
Piracetam is absorbed almost completely and quickly after oral administration. Bioavailability is 100%. When 2 g of the drug is taken orally, the maximum plasma concentration is 40–60 mcg/ml after 30 minutes. Piracetam does not bind to plasma proteins. After 2–8 hours, the maximum concentration in the cerebrospinal fluid is created. Piracetam penetrates into all tissues and organs, and penetrates the placental barrier. Almost not metabolized. Selectively accumulates in the cerebral cortex, mainly in the parietal, frontal and occipital lobes, basal ganglia and cerebellum. The half-life of piracetam from plasma is 4–5 hours; from the cerebrospinal fluid is 6–8 hours. More than 95% of the drug is excreted unchanged by the kidneys after 30 hours. In patients with renal failure, the half-life is prolonged.
